Insense Ltd - Unquoted

Insense has developed an innovative product range for the chronic wound care market - this is a growing market due to, inter alia, the increasing average age of populations and the growing incidence of diabetes. Technology developed by the company has been spun out into Archimed (qv) and Arecor (qv). Following these two spin-outs, Insense is concentrating on using its technology to develop dermatology products for both professional and consumer applications.



Last Updated: 24/07/2018

Investment Information:
date of first inv: Jul 2003
cost: £509,000
valn at: 30/06/2018 £121,000
equity held: 4.6%